Incidence of hyperkalemia in kidney transplant recipients who receive calcineurin inhibitors is about 44% [@bib1]. Ischemia, tubular necrosis, rejection, and drugs are some of the common causes of hyperkalemia. Determining exact cause can guide specific treatment. We describe a case of kidney transplant recipient who had persistent hyperkalemia due to type 4 renal tubular acidosis (RTA) and was treated with fludrocortisone and sodium bicarbonate therapy.

A 66-year-old female diabetic patient presented 2 weeks after kidney transplantation with muscle weakness. Her medications included tacrolimus, mycophenolate mofetil, prednisolone, trimethoprim-sulfamethoxazole, and carvedilol. Her laboratory reports showed serum creatinine 0.6 mg/dl, serum sodium 135 mEq/L, serum potassium 6.5 mEq/L, serum chloride 110 mEq/L, and serum bicarbonate 18 mEq/L.

We stopped co-trimoxazole and carvedilol. She was started on frusemide, oral potassium binding resins, and oral sodium bicarbonate. Serum tacrolimus levels were 7.1 ng/L. Repeat serum potassium reading was 7 mEq/L. Further evaluation showed urine pH 5.1, urine sodium 40 mEq/L, urine potassium 30 mEq/L, and urine chloride 50 mEq/L. The serum anion gap was 7 mEq/L and urinary anion gap was 20 mEq/L. Hyperkalemia distal RTA was ruled out as urinary pH was \<5.5. A normal anion gap metabolic acidosis, positive urinary anion gap with a urine pH of \<5.5 was suggestive of type 4 RTA. We started the patient on fludrocortisone 0.1 mg/day. Serum potassium levels on consecutive days were 5.8 mEq/L, 5.1 mEq/L, and 4.5 mEq/L. Fludrocortisone was gradually tapered after 10 days and stopped. Patient remained normokalemic at follow-up.

Though there are a few case reports, exact prevalence of type 4 RTA in kidney transplant recipients in early posttransplant period is not known [@bib2], [@bib3]. In one study of 109 kidney transplant recipients, RTA was seen in 36 patients and only 3 of these patients had type 4 RTA. Late after transplant, incidence of type 4 RTA in late transplant period can be as high as 28% [@bib4], [@bib5].

In this case, type 4 RTA was probably a result of tacrolimus-induced aldosterone resistance of renal tubules. Finding the etiology of hyperkalemia will make specific treatment possible.
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